Please use this identifier to cite or link to this item:
|Title:||THE USE OF FUSOGENIC LIPIDS AND HDAC6 INHIBITORS TO ENHANCE GENE DELIVERY||Authors:||TAN BING QUAN JUSTIN||Keywords:||HDAC inhibitor, Gene delivery, non-viral gene delivery, fusogenic lipids, lentivirus, mesenchymal stem cells||Issue Date:||13-Feb-2017||Citation:||TAN BING QUAN JUSTIN (2017-02-13). THE USE OF FUSOGENIC LIPIDS AND HDAC6 INHIBITORS TO ENHANCE GENE DELIVERY. ScholarBank@NUS Repository.||Abstract:||There are growing studies with evidence that ex vivo genetic modifications of human cells, improve therapeutic potentials. Conventional viral vectors are favourable, but hindered by large-scale production issues. Currently, lentivirus production relies on transient transfection which are poor and inconsistent. Previously, the barriers to transient transfection of hard-to-transfect cells was systematically identified and eventually mitigated with the use of DOPE/CHEMS and HDAC6 inhibitors in a cationic-polymer based transfection workflow. As an extension, multiple-plasmid transfection was shown to be similarly enhanced, translating to higher lentivirus production. DOPE/CHEMS and SAHA also significantly enhanced transduction of hard-to-transduce cells. Another emerging therapy is the delivery of therapeutic proteins with genetically-modified cellular vehicles like MSC, which are poorly and inconsistently transfected. In our UC-MSC model, DOPE/CHEMS and HDAC6 inhibitors enhanced MSC transfection, resulting in increased functional protein release. Overall, these studies provide novel findings and is translatable to a wide range of applications.||URI:||http://scholarbank.nus.edu.sg/handle/10635/135580|
|Appears in Collections:||Master's Theses (Open)|
Show full item record
Files in This Item:
|TanBQJ.pdf||5.82 MB||Adobe PDF|
checked on May 22, 2019
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.